Effective August 2, 2022, mdxhealth has acquired the Oncotype DX Genomic Prostate Score (GPS) test from Exact Sciences. Additionally, Genomic Health Inc, part of Exact Sciences, will continue to perform the GPS test during the transition. Further communications explaining transition plans will be provided in the coming months. For more details, please review the press release.
Questions? Email: gps@mdxhealth.com

Small sample. Precision insights.

The Oncomap™ test can meet your testing needs by providing actionable answers, from small sample sizes in a timely manner.

Comprehensive analysis of tissue samples is crucial to accurately diagnose cancer and choose the optimal treatment plan. With the rise of precision oncology, genomic profiling is playing an increasingly large role in diagnosis and clinical decision-making. Pathologists often need to answer many questions from a single sample as quickly as possible.

Why choose the Oncomap test?

This test uses next-generation sequencing (NGS) and a broad array of tumor-specific immunohistochemical (IHC) panels and single stains to identify clinically relevant genomic alterations from patient specimens as small as 3 mm2 of tissue with ≥15% tumor content,* about the size of a grain of rice. It provides this information within 7 days,*† usually before the next follow-up visit.

The test can be performed on FFPE samples, including:

  • Recent and archival tissue
  • Core biopsies
  • Fine needle aspirate cell blocks
  • Body fluid cell blocks
  • Bone metastases

Timely results for deliberate treatment decisions

The Oncomap test can provide in-depth insights into alterations of hundreds of cancer-related genes, usually before the patient’s next follow-up visit.

  • Results reported within 7 days*†

  • 257 genes (SNVs, CNVs, fusions, and structural variants)

  • IO signatures, including TMB and MSI

  • 24 IHC stains, including PD-L1 (SP142, 22C3)

  • 100+ therapies

  • 45+ combination therapies

  • 650+ clinical trials

  • >99% sensitivity and specificity,§ even on small samples

  • Compatible with fine needle aspirates and core biopsies

  • FFPE samples as small as 3 mm2 with ≥15% tumor content,* about the size of a grain of rice

Leverage NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®),1 CAP, and ASCO recommendations to help guide evidence-based, genome-informed therapy selection and clinical trials that match your patient’s needs.

Is your patient eligible?

The Oncomap test is for patients who have advanced, metastatic, refractory, relapsed, or recurrent cancer.

Guidance for sample submission

The Oncomap test can be run on samples as small as 3 mm2 with ≥15% tumor content, but larger samples ≥10 mm2) with higher tumor content (≥20%) are preferred, when available. For tissue blocks where the overall tumor content does not meet criteria, microdissection will be performed, if possible.

To reduce delays in testing and subsequent treatment, we recommend that a pathologist select the optimal block for testing. Please reference our sample submission guidelines and choose the FFPE block with the greatest amount/area of the highest-grade carcinoma, morphologically consistent with the submitting diagnosis. Ethylenediaminetetraacetic acid (EDTA) should be used for samples requiring decalcification to preserve nucleic acid and protein expression.

Download the Sample Submission Guidelines

Download the Bone Decalcification Instructions

Coverage and financial assistance

Exact Sciences is committed to supporting patient access to the Oncomap test to help your patients make informed decisions about their treatment.**

View more billing and coverage details